Position in ANAB
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$13,837
New position
Shares Held
205
first reported quarter
Ownership
0.001%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#180
of 210 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Silver Grove Financial Group, Inc. holds $495,408 across 128 Biotechnology names. ANAB ranks #7 (2.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
241 | $119,711 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
37 | $23,070 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
|
149 | $18,264 | |
| 4 | ORKA |
Oruka Therapeutics, Inc.
|
182 | $17,320 | |
| 5 | CYTK |
Cytokinetics Inc
|
180 | $15,334 | |
| 6 | PHAR |
Pharming Group N.V.
|
1,071 | $14,876 | |
| 7 | ANAB |
Anaptysbio, Inc
This page
|
205 | $13,837 | |
| 8 | ZBIO |
Zenas BioPharma, Inc.
|
538 | $13,654 |
All Filings in ANAB
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $13,837 | 205 | Shares | Sole | 2026-08-13 | |
| No filing history on record for this holder in this stock. | ||||||